Treatment of experimental allergic encephalomyelitis with myelin basic protein: Which route is best?
- 1 October 1984
- journal article
- research article
- Published by Springer Nature in Neurochemical Research
- Vol. 9 (10) , 1417-1421
- https://doi.org/10.1007/bf00964668
Abstract
When myelin basic protein (BP) has been used for the treatment of multiple sclerosis (MS), it has been injected intramuscularly (IM) or subcutaneously (SC). Experimental allergic encephalomyelitis (EAE) is widely used as a model for MS, and the use of BP for MS is based on its efficacy in EAE. The present work shows that BP is more effective in EAE when administered by intravenous (IV) route than by IM or SC routes. These observations may be pertinent to therapeutic trials in MS.Keywords
This publication has 17 references indexed in Scilit:
- Metabolism of a peptide of human myeh basic protein in the rabbitNeurology, 1980
- Myelin basic protein treatment of experimental allergic encephalomyelitis in monkeysAnnals of Neurology, 1979
- Has myelin basic protein received a fair trial in the treatment of multiple sclerosis?Annals of Neurology, 1979
- Myelin Basic Protein: Structure, Function and Antigenic DeterminantsImmunological Reviews, 1978
- Failure of basic protein therapy for multiple sclerosisZeitschrift für Neurologie, 1977
- Hyperacute, neutrophilic, and localized forms of experimental allergic encephalomyelitis: A reviewActa Neuropathologica, 1974
- Myelin Basic Protein Administration in Multiple SclerosisArchives of Neurology, 1973
- Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogenEuropean Journal of Immunology, 1973
- Treatment of Experimental Allergic Encephalomyelitis with Encephalitogenic Basic ProteinsExperimental Biology and Medicine, 1972
- Allergic Encephalomyelitis: Passive Transfer Prevented by EncephalitogenScience, 1968